Group 1 - Ikena Oncology, Inc. (IMA) shares have increased by 2.4% over the past four weeks, closing at $16.6, with a mean price target of $132.05 indicating a potential upside of 695.5% [1][2] - The mean estimate includes three short-term price targets with a standard deviation of $125.33, where the lowest estimate suggests an increase of 189.3% and the highest indicates a surge of 1563.3% to $276.11 [2] - Analysts show strong agreement on IMA's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for IMA has increased by 51.5% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - IMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
ZACKS·2025-08-05 14:56